Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Star Combo PharmaASX:S66 20 12-1 Month Momentum % is -38.10% as of Sep. 16, 2026. GuruFocus rates ASX:S66 with a GF Score™ of 20/100 and a GF Value™ of A$0.13 (Fairly Valued). The stock has 4 warning signs investors should review. Among 2,028 Consumer Packaged Goods companies, Star Combo Pharma ranks worse than 86.24% on this metric.
12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2026-09-16), Star Combo Pharma's 12-1 Month Momentum % is -38.10%.
The industry rank for Star Combo Pharma's 12-1 Month Momentum % or its related term are showing as below:
ASX:S66's 12-1 Month Momentum % is ranked worse than 86.24% of 2028
companies
in the Consumer Packaged Goods industry
Industry Median: -7.84
vs ASX:S66: -38.10
Star Combo Pharma (ASX:S66) 12-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Star Combo Pharma 12-1 Month Momentum % Related Terms
ASX:S66 vs PG, CL, EL: 12-1 Month Momentum % Comparison
For the Household & Personal Products subindustry, Star Combo Pharma's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Star Combo Pharma 12-1 Month Momentum % vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Star Combo Pharma's 12-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Star Combo Pharma's 12-1 Month Momentum % falls into.
Star Combo Pharma (ASX:S66) 12-1 Month Momentum % Calculation
12-1 Month Momentum % is calculated as following:
12-1 Month Momentum %
=
( Price 1-month ago
/
Price 12-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a 12-1 Month Momentum % of -38.10% mean?
Star Combo Pharma (ASX:S66) has a 12-1 Month Momentum % of -38.10% as of Sep. 16, 2026. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Star Combo Pharma and its competitors. According to the industry distribution chart, Star Combo Pharma ranks #1749 out of 2028 companies in the Consumer Packaged Goods industry, placing it in the top 86.2%.
Is Star Combo Pharma's 12-1 Month Momentum % too high?
Star Combo Pharma's current 12-1 Month Momentum % is -38.10%. Based on the distribution chart, Star Combo Pharma ranks #1749 out of 2028 companies in the Consumer Packaged Goods industry, which is in the bottom quartile relative to peers. Overall, Star Combo Pharma has a GF Score™ of 20/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Star Combo Pharma's 12-1 Month Momentum % compare to PG and CL?
According to the Consumer Packaged Goods industry distribution chart, Star Combo Pharma ranks #1749 out of 2028 companies for 12-1 Month Momentum %. This places Star Combo Pharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 12-1 Month Momentum % for a Consumer Packaged Goods company?
A good 12-1 Month Momentum % depends on the Consumer Packaged Goods industry context. However, 12-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 12-1 Month Momentum % mean?
A high 12-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Star Combo Pharma and its competitors. Star Combo Pharma's current 12-1 Month Momentum % is -38.10%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Star Combo Pharma stock overvalued right now?
Based on GuruFocus' analysis, Star Combo Pharma (ASX:S66) is currently considered Fairly Valued. The stock's GF Value™ is A$0.13, compared to a current price of A$0.14 — trading 7.7% above its estimated fair value. The current 12-1 Month Momentum % is -38.10%. Star Combo Pharma's overall GF Score™ is 20/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 12-1 Month Momentum % calculated?
12-1 Month Momentum % is calculated from a company's financial statements. For Star Combo Pharma (ASX:S66), the current 12-1 Month Momentum % is -38.10% as of Sep. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Star Combo Pharma (ASX:S66) Overvalued in 2026?
Based on GuruFocus' analysis, Star Combo Pharma stock appears to be overvalued.
The current stock price of A$0.14 is trading 7.7% above its estimated GF Value™ of A$0.13.
GuruFocus considers Star Combo Pharma to be Fairly Valued.
Key valuation signals for ASX:S66:
12-1 Month Momentum %: -38.10%
GF Value™: A$0.13 vs. price of A$0.14 (7.7% above fair value)
No single metric tells the full story. See the ASX:S66 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Star Combo Pharma Ltd is engaged in the manufacturing and distribution of food products and nutritional supplements. The company offers products such as Costar, Living Healthy, Amax, and J&K. It operates in two segments. The Star Combo segment engages in the development, manufacturing, marketing, and sales of natural health supplements and skincare products. The Austoyou retail business segment consists of the Australia-China e-commerce platform that offers product lines directly to Chinese health product consumers, and Koala Mall's two retail stores in Sydney. Geographically, it operates in China and Australia.
20GF Score
Get the complete analysis for ASX:S66
12-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:S66 has been successfully added to your 
